Core Insights - Resmed Inc. reported adjusted earnings per share (EPS) of $2.81 for Q2 fiscal 2026, reflecting a 15.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 4.59% [2] - The company's total revenue for the quarter reached $1.42 billion, marking an 11% year-over-year growth, also exceeding the Zacks Consensus Estimate by 2.30% [3] Revenue Performance - Revenues from the Sleep and Breathing Health segment increased by 11.6% year over year to $1.26 billion, with Devices revenues at $726.2 million, up 8.5% [5] - The Masks and other category generated $529.7 million, up 16.1% year over year, driven by strong growth in both the U.S. and international markets [6] - The Residential Care Software segment saw a revenue increase of 6.6% year over year, totaling $166.9 million [7] Margin and Profitability - The adjusted gross profit rose 17.3% to $890.5 million, with an adjusted gross margin of 62.6%, reflecting a 340 basis point expansion [8] - The adjusted operating profit for the quarter was $521.2 million, up 19.6% year over year, with an adjusted operating margin of 36.6%, expanding by 263 basis points [10] Financial Position - At the end of Q2 fiscal 2026, Resmed had cash and cash equivalents of $1.42 billion, an increase from $1.38 billion at the end of Q1 [11] - The cumulative net cash provided by operating activities was $797.1 million, compared to $634.2 million in the same period last year [11] - The company paid out $88 million in dividends and repurchased 704,000 shares for $175 million during the quarter [12] Strategic Developments - Resmed received FDA clearance for its Personalized Therapy Comfort Settings, marketed as Smart Comfort, aimed at enhancing CPAP comfort settings and improving patient adherence [15] - The performance of the Residential Care Software segment is bolstered by contributions from the Medifox DAN software vertical, targeting sustainable growth [14]